BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AMSilk Closes 5 Million Euro Financing Round


3/17/2011 9:49:29 AM

Martinsried/Munich, Germany, March 17, 2011 / b3c newswire / – AMSilk, a privately-held company specializing in the development and production of high performance materials based on spider silk, is announcing the successful completion of a 5 million Euro Series B financing round. Investors include MIG Fonds 6, MIG Fonds 7 and MIG Fonds 11, as well as AT Newtec. The newly raised funds will secure AMSilk’s advancement and commercialization efforts for its first spider silk-based products.

AMSilk produces and processes SPIDERSILK, high performance biopolymers copied from the proteins of web-weaving spiders. SPIDERSILK has unique properties such as mechanical toughness, chemical resistance and biocompatibility - while being completely biodegradable. AMSilk is able to produce SPIDERSILK in large scale and produce coatings, beads, films, nonwovens, and fibers used to improve existing or to develop completely new products. AMSilk is, together with various partners, developing several applications for this new material. The successful kilogram-scale production and the continuous development of optimized processing parameters since the company foundation in 2008 were important prerequisites for the new series B financing round.

AMSilk produces SPIDERSILK in bacteria using a sustainable and environmentally friendly process that requires no fossil fuel-based chemicals and generates no toxic waste.

"We are excited to continue our partnership with the investors who have supported us since the company formation in 2008,” says Axel Leimer, Managing Director of AMSilk. “There is an urgent need to develop new and superior cleantech products with a smaller environmental footprint and previously unachievable features. The newly raised funds will be used to commercialize our products through partnerships with leading companies across major industries," added Leimer. AMSilk is currently developing a SPIDERSILK coating for certain implants to improve biocompatibility and reduce fibrosis. Additionally, a recent publication in the scientific journal Biomaterials (2011;32(8):2233-40) shows that SPIDERSILK beads are efficient drug delivery vehicles. These two examples illustrate the broad commercial range of the SPIDERSILK material.

The AMSilk technology is presented today at the ‚biomimetics International Industrial Convention 2011’ in Berlin. AMSilk® is a registered trademark of AMSilk GmbH, all rights reserved.

About AMSilk – www.amsilk.com

Spider silk has attracted human interest for thousands of years, mainly due to its toughness and ductility. As with most biomaterials, spider silk has evolved over millions of years resulting in properties that far exceed any man-made material. Until now, it was not possible to utilize this high-performance material for technical applications.

AMSilk is the first company to produce SPIDERSILK biopolymers, copied from the proteins of web-weaving spiders, on an industrial scale. This makes possible a completely new set of technical products as well as major improvements for already existing products.

AMSilk, a spin-off from the Technische Universität München, was founded in 2008 and is located in the IZB in Martinsried near Munich. For more information visit our website at www.amsilk.com.

About our Investors

MIG Verwaltungs AG with operations in Munich, Germany is the initiator of the MIG fonds, a series of venture-capital funds for private investors with an investment focus in German speaking countries. The fund concept of MIG Fonds enables private investors to participate in the growth and value creation potential of unlisted future-oriented technology companies. MIG was founded in 2004 by successful entrepreneurs and has more than EUR 500 million under management. Three MIG fonds are currently invested in AMSilk: MIG AG & Co. Fonds 6 KG; MIG GmbH & Co. Fonds 7 KG; MIG GmbH & Co. Fonds 11 KG

AT Newtec GmbH is a private investment company located in Munich, Germany.

Contact

Axel H. Leimer Managing Director AMSilk GmbH Am Klopferspitz 19 / IZB 82152 Planegg/Martinsried, Germany Tel: +49 (0)89 38156-4430 Email: info@amsilk.com


Read at BioSpace.com


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->